|
|
You are subscribed to receive research study announcements from the National Institutes of Health (NIH) Clinical Center. To learn more about this NIH study #000326-H, or other studies, please call us at 866-444-1132.
Researchers at the National Institutes of Health (NIH) are testing NX-2127, an oral drug that degrades a protein in cancer cells called Bruton’s tyrosine kinase (BTK), instead of inhibiting or blocking it like other drugs. NX-2127 may also stimulate your immune T-cells to attack the cancer.
Eligible Participants:
- Are 18 years or older;
- Are diagnosed with one of the B-cell malignancies as listed below;
- Have relapsed after at least two prior systemic therapies for:
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Waldenström Macroglobulinemia (WM) (only one previous treatment required)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- Follicular Lymphoma (FL)
- Diffuse Large B-cell Lymphoma (DLBCL)
Study Includes:
- Taking NX-2127 by mouth daily for 28-day cycles
- Diagnostic procedures such as blood tests, bone marrow biopsies and CT scans (or PET-CTs as appropriate), lymph node biopsies, EKG, and echocardiogram
- Weekly outpatient visits during the first 8 weeks, and then approximately every 4 weeks after that
Your participation is at no cost, and travel assistance may be available.
|
|
|
For more information:
NIH Clinical Center Office of Patient Recruitment
866-444-1132
TTY users dial 7-1-1
Email: ccopr@nih.gov
Online: https://go.usa.gov/xuPDr
Study # 000326-H
Follow us on Instagram @nih_ccopr
The NIH Clinical Center, America’s Research Hospital located in Bethesda, MD
Metro red line (Medical Center stop)
|
|
|
|
